DeutschClear Cookie - decide language by browser settings
Vanderstichele, Hugo; De Vreese, Karen; Blennow, Kaj; Andreasen, Niels; Sindic, Christian; Ivanoiu, Adrian; Hampel, Harald; Bürger, Katharina; Parnetti, Lucilla; Lanari, Alessia; Padovani, Allesandro; DiLuca, Monica; Bläser, Miriam; Olsson, Annika Ohrfelt; Pottel, Hans; Hulstaert, Frank; Vanmechelen, Eugeen (2006): Analytical performance and clinical utility of the INNOTEST (R) PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. In: Clinical Chemistry and Laboratory Medicine, Vol. 44, No. 12: pp. 1472-1480




Background: Total tau (T-tau) and beta-amyloid((1-42)) (A beta(1-42)) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNOTEST (R) PHOSPHO-TAU((181P)) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and AP1-421 for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau(181P)) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau(181P) was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau(181P) quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.